Media Center

Filgotinib Shows Positive Topline Results Across Full Spectrum of Axial Spondyloarthritis in OLINGUITO Phase 3 Study

Alfasigma Reports Record Growth in First-Ever Financial Results; €1.87 billion Revenue Setting the Stage for Future Growth

ALFASIGMA AT UEG WEEK (Vienna, 12 -15 OCTOBER 2024)

Alfasigma announces the Completion of Marketing Authorisation Transfer for Jyseleca® in the European Union

Alfasigma completes transaction to acquire the Jyseleca® business from Galapagos for up to €170 million

Alfasigma signs an agreement to acquire Jyseleca® business for up to €170 million from Galapagos following October letter of intent